Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
AcouSort AB (ACOU.ST)
Lund, SE
AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an module that enables in-line analysis of blood plasma from whole blood samples; AQC Module, an in-line optical analysis of particle suspensions for quality control or monitoring applications; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company has collaboration agreement with global life science company to develop cell therapy and other elements of the future automated systems. AcouSort AB (publ) was founded in 2010 and is based in Lund, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.21% | -2.39% | +14.21% | +82.93% | +57.34% | +38.46% | +36.36% | -71.70% | -82.82% | -78.37% | -78.37% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+44.7% ★ Q1'26: +34.6% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+36.6% ★ Q1'26: +59.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%-53.9% Q1'26: +400.9% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%-211.6% Q1'26: -146.7% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%-144.9% Q1'26: +1,509.0% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%+26.3% Q1'26: +36.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×0.00× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
3.01M
est: 2.90M (+3.7%)
|
4.96M
est: 6.60M (-24.8%)
|
10.55M
est: 9.90M (+6.6%)
|
4.74M
est: 4.70M (+0.8%)
|
6.85M
est: 6.00M (+14.2%)
|
10.40M
10.40M – 10.40M
+73.3% YoY
|
14.80M
14.80M – 14.80M
+42.3% YoY
|
34.10M
34.10M – 34.10M
+130.4% YoY
|
| EBITDA |
-11.46M
est: -2.90M (-295.0%)
|
-12.86M
est: -6.60M (-94.8%)
|
-16.70M
est: -9.90M (-68.7%)
|
-15.89M
est: -4.70M (-238.1%)
|
-14.33M
est: -6.00M (-138.8%)
|
-10.40M
-10.40M – -10.40M
-73.3% YoY
|
-14.80M
-14.80M – -14.80M
-42.3% YoY
|
-34.10M
-34.10M – -34.10M
-130.4% YoY
|
| EBIT |
-12.09M
est: -2.90M (-317.0%)
|
-13.77M
est: -6.60M (-108.6%)
|
-17.49M
est: -9.90M (-76.6%)
|
-16.13M
est: -4.70M (-243.1%)
|
-14.50M
est: -6.00M (-141.7%)
|
-10.40M
-10.40M – -10.40M
-73.3% YoY
|
-14.80M
-14.80M – -14.80M
-42.3% YoY
|
-34.10M
-34.10M – -34.10M
-130.4% YoY
|
| Net Income |
-12.38M
|
-13.21M
|
-17.09M
|
-15.08M
est: -188.60M (+92.0%)
|
-12.15M
est: -132.02M (+90.8%)
|
-5.66M
-5.66M – -5.66M
+95.7% YoY
|
-3.77M
-3.77M – -3.77M
+33.3% YoY
|
3.77M
3.77M – 3.77M
+200.0% YoY
|
| SGA |
3.72M
est: 6.49M (-42.6%)
|
6.51M
est: 14.76M (-55.9%)
|
25.09M
est: 22.15M (+13.3%)
|
25.96M
est: 9.78M (+165.3%)
|
—
est: 12.49M (-100.0%)
|
21.65M
21.65M – 21.65M
+73.3% YoY
|
30.81M
30.81M – 30.81M
+42.3% YoY
|
70.98M
70.98M – 70.98M
+130.4% YoY
|
| EPS |
-0.93
|
-1.00
|
-1.29
|
-1.01
est: -10.00 (+89.9%)
|
-0.64
est: -7.00 (+90.9%)
|
-0.30
-0.30 – -0.30
+95.7% YoY
|
-0.20
-0.20 – -0.20
+33.3% YoY
|
0.20
0.20 – 0.20
+200.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Torsten Freltoft | Chief Executive Officer | 503.4K | male |
| Gunnar Telhammar | Chief Financial Officer | — | male |
| Hans Lilja | Founder | — | — |
| Patrik Brundin | Founder | — | — |
| Stefan Scheding | Founder & Independent Director | — | — |
| Thomas Laurell | Founder & Independent Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ACOU.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
